138871-58-6

Basic information

• Product Name: (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)Methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate
• Synonyms: (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)Methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate;(2S)-2-[[[(tert-Butyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-oxo-1H-pyrrole-1-carboxylic acid tert-butyl ester
• CAS NO: 138871-58-6
• Molecular Formula: C₂₆H₃₃NO₄Si
• Molecular Weight: 451.63002
• Mol File: 138871-58-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 94-95℃
• Appearance: /
• Density: 1.12
• CAS DataBase Reference: (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)Methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)Methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate(138871-58-6)
• EPA Substance Registry System: (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)Methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate(138871-58-6)

Safety Data

• Hazardous Substances Data: 138871-58-6(Hazardous Substances Data)

Usage

General Description

(S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)Methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate is a chemical compound with a complex structure. It consists of a tert-butyl group attached to a 2-((tert-butyldiphenylsilyloxy)methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate moiety. (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)Methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate is often used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. Its unique structure makes it a valuable building block for the construction of various complex molecules in organic chemistry.

Upstream product

• 7149-65-7 ethyl (S)-pyroglutamate 
• 98-79-3 L-Pyroglutamic acid 
• 4931-66-2 methyl (S)-pyroglutamate 
• 17342-08-4 (S)-Pyroglutaminol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 132974-83-5 (5S)-5-[[(tert-butyldiphenylsilyl)oxy]methyl]pyrrolidin-2-one 
• 138629-30-8 (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)methyl)-5-oxopyrrolidine-1-carboxylate 
• 919349-69-2 (S)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-2-oxo-3-phenylselanyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 138871-57-5 (3R,5S)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-2-oxo-3-phenylselanyl-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 144564-12-5 4S,5S-1-t-butoxycarbonyl-4-butyl-5-t-butyldiphenylsiloxymethylpyrrolidine-2-one 
• 910548-24-2 (4R,5S)-N-tert-butyloxycarbonyl-5-hydroxymethyl-4-methylpyrrolidin-2-one 
• 910548-25-3 (2S,3R)-N-tert-butyloxycarbonyl-3-methylpyroglutamic acid 
• 910548-26-4 (2S,3R)-N-tert-butoxycarbonyl-3-methylglutamic acid 
• 910548-22-0 (2S,3R)-3-methylglutamic acid hydrochloride 
• 910548-22-0 (2S,3S)-3-methylglutamic acid hydrochloride 
• 158038-36-9 (5S)-3,4-dihydro-5-tert-butyldiphenylsilyloxymethyl-N-tert-butyloxycarbonyl-4-methylpyrrolidin-2-one 
• 158135-16-1 (4R,5S)-5-tert-butyldiphenylsilyloxymethyl-N-tert-butyloxycarbonyl-4-methylpyrrolidin-2-one 
• 257882-51-2 (2S)-N-tert-butoxycarbonyl-2-tert-butyldiphenylsiloxymethyl[3,4,5-D₃]pyrrolidine 
• 144564-14-7 (4R,5S)-1-tert-butyloxycarbonyl-5-((tert-butyldiphenylsilyl)oxymethyl)-4-vinylpyrrolidin-2-one 
• 144564-16-9 tert-butyl (4S,5S)-4-allyl-5-((tert-butyldiphenylsilyl)oxymethyl)-2-oxopyrrolidine-1-carboxylate 
• 1344158-05-9 (2S,3R)-2-(tert-butyl-diphenyl-silanyloxymethyl)-3-cyclohexyl-5-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1344158-03-7 (2S,3R)-2-(tert-butyl-diphenyl-silanyloxymethyl)-5-oxo-3-p-tolyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 462123-82-6 (2S,3R)-3-Cyclohexyl-pyrrolidine-2-carboxylic acid 

Relevant articles and documents

STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE PHARMACEUTICAL USE THEREOF

The invention relates to compounds of general formula (I), which can be used particularly as structural mimetics of proline-rich peptides and are therefore capable of binding PRM binding domains (proline-rich motif binding domains) of proteins. The invention also relates to the use of said compounds as pharmaceutical active agents and the use of these pharmaceutical active agents for treating bacterial diseases, neurodegenerative diseases and tumours.

Biosynthesis of the (2S,3R)-3-methyl glutamate residue of nonribosomal lipopeptides

The calcium-dependent antibiotics (CDAs) and daptomycin are therapeutically relevant nonribosomal lipopeptide antibiotics that contain penultimate C-terminal 3-methyl glutamate (3-MeGlu) residues. Comparison with synthetic standards showed that (2S,3R)-co

Asymmetric synthesis from α-amino acids; Some reactions of (S)-pyroglutamate

-